Ann: Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX, page-3

Awesome.
After 6 weeks (day 43) treatment with PD1-Vaxx, one patient’s tumor was non-measurable indicating a complete response (CR), with three patients showing stabilization of disease (SD) and a single patient progressing (PD). The status of two patients from cohort 1 (1 x SD, 1 x CR) were unchanged at day 85.

These are encouraging results in patients who have progressed after previous treatment with checkpoint inhibitors including Keytruda®, Opdivo® or Tecentriq®. Further results and scans are scheduled over the coming weeks. The clinical results indicate that PD1-Vaxx is showing early signs of an immune responses in patients, with antibodies to the target biomarker PD1 evident in validated assays.

Imugene MD & CEO Leslie Chong said “Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial”.